The Schedule and Duration of Intravesical Chemotherapy in Patients with Non-Muscle-Invasive Bladder Cancer: A Systematic Review of the Published Results of Randomized Clinical Trials

European Urology

Volumn 53, Issue 4, 2008, Pages 709-719

  Sylvester, Richard J ^a   Oosterlinck, Willem ^b   Witjes, J Alfred ^c  

^a EORTC DATA CENTER   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Intravesical chemotherapy; Non muscle invasive bladder cancer; Recurrence; Schedule; Systematic review

Indexed keywords

DOXORUBICIN; EPIRUBICIN; ETOGLUCID; MITOMYCIN; THIOTEPA;

BLADDER CANCER; BLADDER MUSCLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG INSTILLATION; HUMAN; LONG TERM CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REVIEW; SYSTEMATIC REVIEW; TRANSURETHRAL RESECTION; TREATMENT DURATION;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; CHI-SQUARE DISTRIBUTION; DRUG ADMINISTRATION SCHEDULE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 39549083897     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.01.015     Document Type: Review

References (41)

1. Oosterlinck W., van der Meijden A., Sylvester R., et al. Guidelines on TaT1 (non-muscle invasive) bladder cancer. European Association of Urology (2006)
2. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477
3. Sylvester R.J., Oosterlinck W., and van der Meijden A.P.M. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 171 (2004) 2186-2190
4. Pawinski A., Sylvester R., Kurth K.H., et al. A combined analysis of European Organization for Research and Treatment of Cancer and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J Urol 156 (1996) 1934-1941
5. Huncharek M., Geschwind J.F., Witherspoon B., McGarry R., and Adcock D. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. J Clin Epidemiol 53 (2000) 676-680
6. Huncharek M., McGarry R., and Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res 21 (2001) 765-770
7. Lamm D.L., Riggs D.R., Traynelis C.L., and Nseyo U.O. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 153 (1995) 1444-1450
8. Medical Research Council Working Party on Urological Cancer, and An MRC study. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. Br J Urol 57 (1985) 680-685
9. Medical Research Council Working Party on Urological Cancer, Subgroup on Superficial Bladder Cancer. The effect of intravesical thiotepa on tumor recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Br J Urol 1994;73:632-8.
10. Tolley D.A., Hargreave T.B., Smith P.H., et al. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br Med J 296 (1988) 1759-1761
11. Tolley D.A., Parmar M.K.B., Grigor K.M., Lallemand G., and the Medical Research Council Superficial Bladder Cancer Working Party. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of followup. J Urol 155 (1996) 1233-1238
12. Selvaggi F.P., de Micheli P., Pamparana F., and Sacchetti G. Epirubicina endovesicicale nella profilassi delle recidive dei tumori superficiali della vesica. Studio multicentrico, randomizzato. Acta Urol Ital 1 Suppl 1 (1990) 331-333
13. Bouffioux C., Kurth K.H., Bono A., et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. J Urol 153 (1995) 934-941
14. Okamura K., Kinukawa T., Tsumura Y., et al. A randomized study of short- versus long-term intravesical epirubicin instillation for superficial bladder cancer. Eur Urol 33 (1998) 285-289
15. Koga K., Kuroiwa K., Yamaguchi A., Osada Y., Tsuneyoshi M., and Naito S. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder. J Urol 171 (2004) 153-157
16. Ali-el-Dein B., Nabeeh A., El-Baz M., Shamaa S., and Ashamallah A. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumors: a prospective, randomized controlled study. Br J Urol 79 (1997) 731-735
17. Liu B., Wang Z., Chen B., et al. Randomized study of single instillation of epirubicin for superficial bladder carcinoma: long-term clinical outcomes. Cancer Invest 24 (2006) 160-163
18. Hendricksen K., Kiemeney L.A., Caris C., Janzing R., Witjes W., and Witjes J.A. Three schedules of adjuvant intravesical epirubicin in patients with non-muscle invasive bladder cancer: a comparative study. Eur Urol Suppl 6 (2007) 60 abstract no. 149
19. Iborra Juan I., Ricos Torrent J.V., Monros Lliso J.L., Dumont Martinez R., Ramon-Borja J.C., and Solsona Narbon E. Resultados de un studio de quimioprofilaxis intravesical, prospectivo, doble aleatorio, entre dos drogas: la adriamicina y el mitomycin; y dos modos de iniciar las instilaciones: precoz y tardio. Efecto sobre la recidiva y la progresion. Arch Esp de Urol 45 (1992) 1001-1007
20. Ueda T., Naito S., Iguchi A., et al. Adjuvant chemotherapy with early intravesical instillation of adriamycin and long-term oral administration of 5-fluorouracil in superficial bladder cancer. Cancer Chemother Pharmacol 30 suppl (1992) S31-S36
21. Nomata K., Noguchi M., Kanetake H., et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of a randomized trial with epirubicin comparing short-term versus long-term maintenance treatment. Cancer Chemother Pharmacol 50 (2002) 266-270
22. Rubben H., Lutzeyer W., Fischer N., et al. Natural history and treatment of low and high risk superficial bladder tumors. J Urol 139 (1988) 283-285
23. Kuroda M., Niijima T., Kotake T., Akaza H., and Hinotsu S. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer-the 6th trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20 mg/40 ml, 30 mg/40 ml, 40 mg/40 ml. Eur Urol 45 (2004) 600-605
24. Flamm J., Kuhnel W., and Dona S. Kurzzeit-versus langzeitchemorezidiv-prophylaxe mit epodyl nach TUR beim oberflachlichen harnblasenkarzinom. Urologe A 28 (1989) 99-102
25. Flamm J. Long-term versus short-term doxorubicin hydrochloride instillation after transurethral resection of superficial bladder cancer. Eur Urol 17 (1990) 119-124
26. Huland H., Kloppel G., Feddersen I., et al. Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients. J Urol 144 (1990) 68-72
27. Schwaibold H., Pichlmeier U., Klingenberger H.J., and Huland H. Long-term follow-up of cytostatic intravesical instillation in patients with superficial bladder carcinoma. Is short-term, intensive instillation better than maintenance therapy?. Eur Urol 31 (1997) 153-159
28. Friedrich M.G., Pichlmeier U., Scwaibold H., Conrad S., and Huland H. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder carcinoma. Eur Urol 52 (2007) 1123-1130
29. Mitsumori K., Tsuchiya N., Habuchi T., et al. Early and large-dose intravesical instillation of eoirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection. BJU Int 94 (2004) 317-321
30. Au J.L.S., Badalament R.A., Wientjes M.G., et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 93 (2001) 597-604
31. Akaza H., Isaka S., Koiso K., et al. Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Cancer Chemother Pharmacol 20 Suppl (1987) 91-96
32. Niijima T., Koiso K., and Akaza H. Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer. Cancer Chemother Pharmacol 11 Suppl (1983) 79-82
33. Ali-el-Dein B., El-Baz M., Aly A.N.M., Shamaa S., and Ashamallah A. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study. J Urol 158 (1997) 68-74
34. Koontz W.W., Prout G.R., Smith W., Frable W.J., and Minnis J.E. The use of intravesical thio-tepa in the management of non-invasive carcinoma of the bladder. J Urol 125 (1981) 307-312
35. van der Meijden A.P.M., Brausi M., Zambon V., Kirkels W., de Balincourt C., and Sylvester R. Intravesical instillation of epirubicin, bacillus Calmette-Guérin and bacillus Calmette-Guérin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer Genito-Urinary Group randomized phase III trial. J Urol 166 (2001) 476-481
36. Masters J.R.W., Popert R.J.M., Thompson P.M., Gibson D., Coptcoat M.J., and Parmar M.K.B. Intravesical chemotherapy with epirubicin: a dose response study. J Urol 161 (1999) 1490-1493
37. Brausi M., Collette L., Kurth K., et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 41 (2002) 523-531
38. Jakse G., Algaba F., Malmström P.U., and Oosterlinck W. A second-look TUR in T1 transitional cell carcinoma: why?. Eur Urol 45 (2004) 539-546
39. Divrik T., Yildirim U., Eroglu A., Zorlu F., and Ozen H. Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer. J Urol 175 (2006) 1258-1261
40. Solsona E., Iborra I., Ricos J.V., Monros J.L., Casanova J., and Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 161 (1999) 1120-1123
41. Hinotsu S., Akaza H., Ohashi Y., and Kotake T. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection. Cancer 86 (1999) 1818-1826